The UK is gearing up for an unprecedented public health initiative as concerns grow over a surge in Meningitis B cases this year, particularly in Kent and other parts of the country. To address this worrying trend, a one-off vaccination programme will offer approximately one million young people protection against the potentially life-threatening disease.
The vaccine drive will primarily target pupils completing Year 13 in England and Wales, Year 14 in Northern Ireland, and S6 in Scotland during the summer of 2026. Additionally, young people aged 18 to 25 who are embarking on their first year at university or moving into residential further education settings in autumn 2026 will also be eligible. This proactive measure acknowledges the increased risk faced by young adults in new communal living and social environments, where the bacteria can spread more easily through close contact.
Meningitis B is a severe bacterial infection that can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicaemia (blood poisoning). The disease can progress rapidly and have devastating consequences. According to NHS data, there were 1,144 cases of Meningitis B reported in England between January 2024 and March 2026, resulting in 13 deaths. This highlights the critical need for targeted vaccination efforts against specific strains.
The MenB vaccine requires two doses for maximum protection, administered at least 28 days apart. In England, vaccinations will be offered through community pharmacies in July and August, with no requirement to attend the same pharmacy for both jabs. Year 13 students will receive direct invitations via NHS app, text, email, or letter, while eligible under-25s starting university can book appointments directly with pharmacies. International students under 25 entering their first year are advised by the UK Health Security Agency (UKHSA) to receive their first dose before arriving in the UK, if possible.
While this one-off programme has been welcomed by campaigners like Lana Quinlan, who continues to suffer from chronic migraines and memory loss after contracting meningitis at university, there are calls for the MenB vaccine to become a permanent fixture in the routine immunisation schedule. The targeted rollout of the MenB vaccine is a crucial step towards protecting young people against this potentially life-threatening disease.